News & Updates
Filter by Specialty:
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
07 Sep 2022Pandemic-fueled psych problems, fear of recurrence common among cancer patients
Psychological problems, such as post-traumatic stress disorder (PTSD), depression, and anxiety, are common among cancer patients during the COVID-19 pandemic, as were fears of disease progression or recurrence, a recent study has found.
Pandemic-fueled psych problems, fear of recurrence common among cancer patients
02 Sep 2022Could tixagevimab–cilgavimab prevent progression to severe COVID-19 in unvaccinated adults?
The combination of tixagevimab and cilgavimab, two SARS-CoV-2 neutralizing monoclonal antibodies, appeared to protect against progression to severe disease or death in non-hospitalized, unvaccinated adults presenting with mild-to-moderate COVID-19, results of the ongoing phase III TACKLE trial showed.
Could tixagevimab–cilgavimab prevent progression to severe COVID-19 in unvaccinated adults?
01 Sep 2022Do eyeglasses act as a shield against SARS-CoV-2 infection? Maybe—or maybe not
There is inconclusive evidence that wearing one’s eyeglasses can lower their chances of contracting COVID-19, according to a recent study.
Do eyeglasses act as a shield against SARS-CoV-2 infection? Maybe—or maybe not
01 Sep 2022Mental health of youths impaired during pandemic
Poor health-related quality of life (HRQoL), along with high levels of anxiety and other mental health problems, has become more common among children and adolescents during the COVID-19 pandemic, according to a recent German study.
Mental health of youths impaired during pandemic
01 Sep 2022Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19
In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.
Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19
29 Aug 2022Early transition to oral antimicrobials prevents treatment failure in children with SAB, AHO
Children with Staphylococcus aureus bacteraemia (SAB), a common complication of acute hematogenous osteomyelitis (AHO), are vulnerable to a wide range of illnesses, suggests a study. Thus, classifying its severity may aid in treatment decision-making.